(AOF) – Erytech Pharma is up 1.23% to 0.82 euro after announcing that all the resolutions for which the Board of Directors recommended a favorable vote were adopted by its shareholders during the Combined General Meeting held on June 23, 2023, including the approval of the merger with Pherecydes. The company is renamed Phaxiam Therapeutics, with the objective of becoming “a world leader in phage therapy”. The merger between Erytech and Pherecydes was approved on the basis of an exchange parity of 4 Pherecydes shares for 15 Erytech shares.
During the AGM of Pherecydes which was held following that of Erytech, all the resolutions proposed by the Board of Directors were approved, including those relating to the merger, which entails the dissolution without liquidation of Pherecydes, it being specified that the merger is, for accounting and tax purposes, retroactive to January 1, 2023.
The new Phaxiam Therapeutics shares resulting from the merger will be admitted to trading on compartment C of Euronext Paris under the ISIN code FR0011471135 on June 29, 2023. The settlement-delivery of the new Phaxiam Therapeutics shares will take place on July 3, 2023.